Understanding resistance in PARP inhibitor therapy
Multigene panel testing valuable regardless of age, cancer history
Increased invasive disease-free survival, disease-free survival and overall survival
10-year outcomes favor autologous over implant
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Trial may lead to first FDA approval in this realm
Fat necrosis is a benign but real concern
Phase 1b trial shows good response rate
Cardiac dosing 50 percent below national average
Full treatment in five fractions
Investigating cell-free nucleic acids for cancer detection
Advertisement
Advertisement